The OBR Blog

January 05, 2014 - 07:01 pm Posted in Featured comments0 Comments

In an effort to provide you with timely market feedback from ASH 2013, OBR and MDoutlook are pleased to share results from MDoutlook’s second OncoPoll™ from the meeting exploring Chronic Lymphocytic Leukemia.

Global Response from 24 Countries and 100 Respondents

ROE

• Austria, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Lithuania, Norway, Portugal, Romania, Serbia, Spain, Sweden, Switzerland, Turkey

ROW

• Argentina, Australia, Uruguay

Respondent Practice Classification and Meeting Attendance: Higher Attendance Amongst Ex-US Respondents Than US

Survey Question: How would you classify your practice setting? Did you attend the 55th ASH Annual Meeting in New Orleans, LA?

Key Conclusions

  • More US respondents practiced in community settings rather than academic ones.
    More than 1/3rd attended the ASH annual meeting
  • Ex-US had a 2:1 split between academic and community settings.
    2/3rd of Ex-US respondents attended the ASH annual meeting

1) Chronic Lymphocytic Leukemia Patient Flow: “Watch and wait” CLL Patients Represent Largest Proportion for US and Ex-US

Survey Question: In the past 12 months how many CLL patients have you attended fall into each of these sub-groups?

Key Conclusions

  • “Watch and wait” CLL patients are largest subset of the patient population seen by both US and
    Ex-US respondents
  • Nearly 50% of the CLL patients seen by both US and Ex-US are in “Go go” and “Slow go” category
  • Patient distribution roughly similar for US and Ex-US respondents

2) New Therapies: Obinutuzumab Expect to Have Large Impact on Treatment of “Slow go” Chronic Lymphocytic Leukemia

Survey Question: Based on the data presented at the 55th ASH meeting how impactful do you think Obinutuzumab and Ofatumumab will be for “Slow go” CLL patient group? (Please rate 1=No impact to 5=Great impact)

Key Conclusions

  • Both US and Ex-US respondents rated the impact of obinutuzumab higher than the impact of ofatumumab for the treatment of “Slow go” Chronic Lymphocytic Leukemia patients
  • Nearly 90% of US and Ex-US respondents rated obinutuzumab 4 or 5

3) Anti-CD20 Antibody Therapy: Large Shifts Seen in Usage of Obinutuzumab and Ofatumumab

Key Conclusions

  • US respondents plan to decrease the usage of rituximab by 38% and increase obinutuzumab and ofatumumab almost by 275% and 175% respectively
  • Ex-US respondents plan to decrease the use of rituximab by 20% and increase obinutuzumab and ofatumumab nearly by 375% and 175% respectively

4) Anti-CD20 Antibody Therapy: Future Usage of Obinutuzumab and Ofatumumab is Higher in US than Ex-US

Key Conclusions

  • Based on the clinical availability of obinituzumab and ofatumumab, nearly 50% of US respondents plan to use rituximab and obinutuzumab; ~30% will use ofatumumab
  • Nearly 60% of Ex-US respondents plan to use rituximab; ~30% will use obinutuzumab and ofatumumab
  • Anticipated usage of new therapies will be higher in US than Ex-US

5) New Therapies: Both Ibrutinib and Idelalisib are Expected to Have Large Impact on Treatment of “No go” Chronic Lymphocytic Leukemia

Survey Question: Based on the data presented at the 55th ASH meeting how impactful do you think ibrutinib and idelalisib will be for “No go” CLL patient group? (Please rate 1=No impact to 5=Great impact)

Key Conclusions

  • Both US and Ex-US respondents rated the impact of ibrutinib higher than the impact of idelalisib for the treatment of “No go” CLL patients
  • Ibrutinib impact rating is relatively high for a therapy in phase II clinical trials
    • Over 90% of US and Ex-US respondents rated ibrutinib 4 or 5

6) New Therapies: Majority of Respondents Are Expected to Use Ibrutinib and Idelalisib for CLL Patients with DEL17p and NL17p

Survey Question: Ibrutinib has recently been granted FDA approval for the treatment of Mantle Cell Lymphoma and Idelalisb looks likely to also to receive FDA approval in the near future.  If these two therapies become available to you, what proportion of your patients do you expect to use these treatments?

Key Conclusions

  • More than 80% of US and about 70% of Ex-US CLL patients with DEL17p are expected to receive ibrutinib and/or idelalisib
  • Nearly 2/3rd of CLL patients with NL17p are expected to receive ibrutinib and/or idelalisib in the US and Ex-US

7) New Therapy: ABT-199 Is Expected to Have Large Impact On Treatment of Chronic Lymphocytic Leukemia

Survey Question: Based on the data presented at the 55th ASH meeting how would you rate the impact of ABT-199 for your CLL patients? (Please rate 1=No impact to 5=Great impact)

Key Conclusions

  • ABT-199, an inhibitor of Bcl-2, was highly and equally rated by both US and Ex-US respondents for the treatment of previously treated patients with DEL17p as well as relapsed/refractory patients previously treated with fludarabine
  • Nearly 70% of US and Ex-US respondents rated ABT-199 as 4 or 5; considered high for a treatment in Phase 1 clinical development

For a more detailed analysis, please click here to download the full report.

Submitted by Jan Heybroek, President, Luan Dao, Sr. Global Medical Analyst, and Raj Manimaran, Global Medical Analyst, MDoutlook

article register

Recent Posts

Recent Comments

Archives

Categories